SEC Filing Summary

This filing details transactions by Third Rock Ventures V, L.P. and Third Rock Ventures VI, L.P. concerning Rapport Therapeutics, Inc. common stock. On April 17, 2026, under a Rule 10b5-1 trading plan, 426,005 shares were disposed of at a weighted average price of $40.317. Following these transactions, Third Rock Ventures VI, L.P. holds 969,218 shares directly. The filing also notes that various general partners and managing entities associated with Third Rock Ventures disclaim beneficial ownership beyond their pecuniary interests. The transactions were signed off on April 21, 2026, by Kevin Gillis, representing the general partners.